Amneal Pharmaceuticals, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q2 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Amneal Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2017 to Q2 2024.
  • Amneal Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $3.62M.
  • Amneal Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $17.6M, a 414% increase year-over-year.
  • Amneal Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $8.45M, a 26.9% increase from 2022.
  • Amneal Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was $6.66M, a 40.5% decline from 2021.
  • Amneal Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was $11.2M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $17.6M $3.62M +$3.64M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $13.9M $6.16M +$5.49M +822% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $8.45M $9.88M +$11.7M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 -$3.23M -$2.08M -$6.65M -145% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $3.42M -$23K -$7.37M -100% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $10.8M $668K +$4.13M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $6.66M -$1.8M -$5.94M -143% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $12.6M $4.57M +$521K +12.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $12.1M $7.35M +$4.7M +178% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $7.38M -$3.46M -$3.82M -1064% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $11.2M $4.14M +$2.66M +179% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $8.54M $4.05M +$3.91M +2712% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $4.64M $2.65M +$462K +21.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $4.17M $359K +$109M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 -$104M $1.49M -$6.31M -80.9% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-03
Q3 2020 -$98.1M $144K -$390M -100% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $291M $2.19M +$7.89M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $284M -$108M -$99.7M -1183% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $383M $7.79M +$2.27M +41.1% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $381M $390M +$385M +7527% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$3.5M -$5.7M +$6.72M +54.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$10.2M -$8.43M -$8.79M -2415% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$1.42M $5.52M +$5.52M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 -$6.94M $5.11M +$5.85M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$12.8M -$12.4M -$14.3M -770% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-05
Q1 2018 $1.48M $364K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $0 Oct 4, 2017 Dec 31, 2017 10-K 2018-03-09
Q3 2017 -$738K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $1.85M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.